1 February 2009: With reference to stock exchange notice of 16 January 2009, regarding subscription period and the prospectus related to the rights issue.

As previously communicated, NorDiag has offered a minimum of 50,000,000 and a maximum 120,234,510 new shares at a subscription price of NOK 0.50 in a public offering with pre-emptive rights for the company's shareholders as of 19 December 2008. Together with new shares, the subscribers have been invited to subscribe for warrants in NorDiag.

Results of the rights issue:
After the close of the subscription period Friday 30 January 2009, a total of 67,214,127 shares has been subscribed for, of which 50,000,000 were subscribed for under the underwriting syndicate. Consequently, the share capital of NorDiag will increase from NOK 5,343,755.90 to NOK 12,065,168.60, divided between a total of 120,651,686 outstanding shares with a nominal value of NOK 0.10. A letter with details on allotment will be sent to all subscribers today.

CEO Mårten Wigstøl is satisfied with the result of the rights issue in view of the current economic climate: "The timing has not been the best for this rights issue, but nevertheless it has been a successful capital increase; with Orion Securities as manager. Subscriptions totalled NOK 33.6 million worth of shares, and we regard the high number of investors behind the subscriptions as a positive signal. The capital injection provides us with sufficient liquidity to continue our international commercialization.  Our focus is on continuing the healthy growth trend from Q4-08, and solid results will sooner or later have a positive effect on our share price, which might make it attractive to exercise warrants, hence give us a further effect of this rights issue", he concludes.

The share issue, including payment and transfer of shares, is expected to be completed around 13 February 2009.

Allotment of warrants:
Each new share subscribed for and allocated gives the right to subscribe for and receive, 0.5 warrant with duration until the end of September 2009 (Class A Warrants) and 0.5 warrant with duration until the end of June 2010 (Class B Warrants). Both warrants have the same strike price of NOK 0.5.

As a consequence of the share subscription in the rights issue, 38,607,058 Class A Warrants have been allotted, of which 5,000,000 have been allotted to the underwriting syndicate as underwriting commission. In addition, 38,607,058 Class B Warrants have been allotted, of which 5,000,000 have been allotted to the underwriting syndicate as underwriting commission.

Further, subscriptions for 4,080,000 Class C Warrants have been received from employees of the company and its subsidiaries. Reference is made to announcement made on 15 January 2009 (12:24).

The warrants issue is expected to be completed in parallel with the
transfer of shares, i.e. approximately 13 February 2009.

Contact:
CEO Mårten Wigstøl
Phone +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has also offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information, please see www.nordiag.com.

Read the notice in Norwegian here